ICU Equipment in Massachusetts

Summit International Medical Technologies is a specialty medical device manufacturer focused on critical care, anesthesia, dialysis, and neonatal markets. The company develops, manufactures, and distributes clinically innovative disposable and durable medical products designed to enhance patient safety and clinician efficiency while providing cost-effective care solutions. Key product lines include: Covalon AquaGuard moisture barrier systems for IV sites, PICC lines, and wound dressings; Parasol Medical fall prevention systems (wired and wireless) and DrySmart incontinence management pads; Starboard Medical temperature management probes for patient monitoring; Summit Medical AngelTip Safety Fistula for dialysis access; SternaSafe Uni sternum support braces for post-sternotomy recovery and SternaBra for women; Parasol Medical Cultivate quality assurance products for aseptic procedures; and NDI disposable marking spheres for surgical navigation and tracking. The company also acquired the Critical Concepts Inc. neonatal distribution product line in 2020, expanding its NICU offerings. Summit operates primarily in the United States, serving hospitals, critical care units, dialysis centers, and surgical facilities. The company emphasizes clinician-trusted, easy-to-use solutions with measurable clinical outcomes such as reduced complications, faster patient recovery, and improved safety. Products are designed for both acute hospital settings and post-operative care environments.

Patient Safety Systems Inc manufactures fall prevention and therapeutic support systems for healthcare facilities. The company specializes in safety covers and pressure relief mattresses designed to reduce patient fall risk and provide comfort during therapy and recovery. Their product portfolio includes the Safe & Secure Safety Cover line (5 different styles) and Flotation Air mattress systems with optional heel-off technology. All Flotation Air and Flotation Air Plus mattresses are supplied with integrated Safe & Secure Safety Covers. These systems employ pneumatic flotation technology with whisper-quiet pumps to support pressure management and patient positioning. The company serves acute care hospitals, rehabilitation centers, and long-term care facilities, positioning itself as a specialty support and fall prevention provider. Products are clinically proven and designed for diverse patient needs ranging from standard to complex care requirements.

LeviSense Medical develops an advanced instrumented bed system designed to prevent and treat pressure injuries (pressure ulcers/bed sores) through high-resolution sensing and automated surface control. The LeviSense Pro-Daptive™ SensorCell™ Flotation Surface continuously scans patient form, position, and movement multiple times per second, automatically adjusting the support surface to redistribute pressure and protect vulnerable areas without requiring caregiver intervention. The system features 16 programmable sections for patient-specific customization, Dynamic Offloading™ for automated pressure relief, and Heel Flotation™ for targeted protection. Key benefits include reduced nursing labor demands, decreased repositioning-related injury risk to patients and caregivers, and enhanced patient comfort through advanced envelopment technology. Compatible with standard hospital and home bed frames, the system integrates remote monitoring capabilities and is designed for seamless deployment across ICU through home-care settings, supporting institutional and home-based care delivery models.

Guldmann North America is a specialized provider of safe patient handling and mobility solutions for healthcare environments. Founded in 1980 and headquartered in Tampa, Florida with offices in Medford, Massachusetts, the company delivers ceiling hoists, mobile lifters, patient slings, and comprehensive accessories designed for emergency care, intensive care, operating rooms, rehabilitation, and long-term care settings. Guldmann emphasizes early mobilization protocols that improve patient recovery outcomes while reducing caregiver injury risk through ergonomic design. Beyond equipment, the company offers integrated services including project consultancy, installation, training in safe patient handling techniques, and on-site support. With a global distributor network spanning Iceland to Australia and substantial service capabilities, Guldmann positions itself as one of the world's largest providers of ceiling hoist system installation and maintenance, serving hospitals, care facilities, and home care environments.

Medovate Limited is a UK-based medical device development and commercialization company specializing in bringing novel clinical innovations to market through structured partnerships with NHS clinicians and healthcare providers. The company operates across the full medical device development pipeline—from initial concept evaluation and clinical development through regulatory approval and global market launch. Medovate's current product portfolio includes Safira® (regional anesthesia injection safety system with automatic pressure limiting to reduce nerve injury risk), Glucosave® (critical care blood sampling safety device to prevent inappropriate insulin administration), Humidicare® (heat and moisture exchanger with visual alerts for mechanical ventilation circuits), LUMEVAC™ (endoscopic surgical device for management of life-threatening gastrointestinal tract infections), and CamPROBE (transperineal prostate biopsy facilitation device). The company leverages deep relationships with NHS institutions to validate medical needs, conduct clinical trials, and accelerate adoption of approved technologies. Medovate focuses on patient safety innovations and clinician-centered design, with demonstrated capability in securing regulatory clearance and driving market entry across multiple therapeutic domains including anesthesia, critical care, endoscopic surgery, and urology. The firm's model emphasizes unmet clinical needs resolution and cost-effective solutions for healthcare systems globally.

Surgicure Technologies, Inc. is a medical device company specializing in airway management solutions for civilian and military healthcare applications. The company's flagship product, the HORSESHOE™, is a novel endotracheal (ET) tube securement device designed to address critical safety and comfort challenges in critical care settings. The HORSESHOE™ features a patented off-the-face horseshoe-shaped design with a robust locking mechanism, integrated molar props, and an adjustable track that accommodates ET tubes sized 6.5 to 10 mm. The device is engineered to eliminate medical device-related pressure injuries (MDRPIs) on the face by operating independent of facial skin or lip contact, eliminating the need for adhesives, tape, wires, or additional dressings that commonly cause pressure points and irritation. The HORSESHOE™ facilitates rapid ET tube repositioning via its smooth locking track, enabling assessment and cleaning of facial skin while maintaining airway security. Clinical applications include support for chemotherapy patients with TENS devices, patients with facial trauma, pressure injuries, burns, beards, and emaciated patients. The device supports essential VAP (ventilator-associated pneumonia) prevention practices per 2022 ICHE Guidelines and complies with International NPIAP MDRPI Prevention Guidelines. Surgicure is backed by prominent venture investors including Techstars, BakerBridge Capital, NSF Innovation Corps, and others. The company operates from Cambridge, Massachusetts, and is committed to reducing unplanned extubations, enhancing patient comfort, and standardizing ET tube stabilization practices across critical care environments.

CardioRenal Systems develops the RenalPro (RenalGuard outside the US) autonomously-controlled fluid management and therapeutic system designed to prevent acute kidney injury (AKI) across multiple clinical settings. RenalPro is an FDA-designated breakthrough device that responds to minute fluctuations in urine output while automatically adjusting IV fluid administration in 1 mL increments to maintain hemodynamic stability and prevent over- or under-hydration. The company's primary focus is cardiac surgery-associated AKI (CSA-AKI), where approximately 30% of patients suffer kidney injury post-operatively. In a randomized 220-patient UK study, RenalPro demonstrated a 52% reduction in AKI compared to standard care with no reported adverse events. The system also addresses contrast-associated AKI (CA-AKI) in catheterization lab procedures and shows potential for ICU-related AKI prevention in septic and critically ill patients. RenalPro integrates into existing clinical workflows and represents an alternative to traditional KDIGO bundle protocols, which demonstrate limited efficacy. The company holds ISO 13485 certification and FDA breakthrough device designation, positioning it as a specialized solution for kidney injury prevention in surgical and interventional cardiology settings.

Etiometry, Inc. is a Boston-based medical technology company specializing in AI-driven clinical decision-support software for intensive care units (ICUs). The Etiometry Platform (T3 Platform) aggregates real-time patient data from bedside monitors, peripheral devices, and EHR systems into a unified dashboard powered by Bayesian models and proprietary AI algorithms. The platform computes personalized risk indices to enable proactive care management in both pediatric and adult critical care settings. Core features include data aggregation and visualization, risk analytics for hemodynamic and respiratory management, automated clinical pathway workflows aligned with hospital protocols, and quality improvement analytics. The platform has received 11 FDA 510(k) clearances and CE marking, and has been deployed across 150+ clinical studies leveraging 150+ million hours of de-identified patient data. Clinical evidence demonstrates up to 36% reduction in length of stay, 41% decrease in ICU readmissions, 30% reduction in mechanical ventilation time, and 29% shorter vasoactive infusion duration. Trusted by leading academic medical centers and top-ranked children's hospitals across North America, Europe, and Asia.

Abiomed is a leading manufacturer of percutaneous mechanical circulatory support systems, headquartered in Danvers, Massachusetts. The company specializes in the Impella family of heart pumps—catheter-based, minimally invasive devices designed to provide hemodynamic support and left ventricular unloading in acute heart failure, cardiogenic shock, and high-risk percutaneous coronary intervention (PCI) settings. Impella represents the world's smallest heart pump technology and is used to facilitate myocardial recovery and protect native heart function during complex cardiac procedures. The company's product portfolio includes multiple Impella configurations targeting different clinical scenarios, from acute myocardial infarction and cardiogenic shock to elective protected PCI in patients with severe coronary artery disease or advanced heart failure. Abiomed provides comprehensive clinical support services including on-site, on-call, and online technical and clinical assistance to healthcare professionals. The company maintains a global footprint with major operational centers in the United States (Danvers, Woburn, Baltimore), Europe (Aachen, Berlin), and Japan. Abiomed is a Johnson & Johnson MedTech company and operates within the cardiac support and interventional cardiology market. Clinical evidence demonstrates long-term survival benefits and myocardial recovery outcomes associated with Impella-supported procedures, supported by randomized controlled trials and registry data presented at major cardiology conferences.

TransMedics Group, Inc. is a medical technology company headquartered in Andover, Massachusetts, specializing in organ preservation and transplantation. The company manufactures the Organ Care System (OCS)—an FDA-approved, portable ex vivo perfusion platform that maintains donor organs in a near-physiologic state outside the body. TransMedics offers specialized OCS systems for lung, heart, and liver transplantation, addressing critical limitations of traditional cold storage by reducing ischemic injury, improving organ viability assessment, and enabling long-distance organ retrieval. The company also operates the National OCS Program (NOP), providing comprehensive end-to-end technology and clinical support services to transplant centers, including organ procurement logistics, clinical expertise, and resource optimization. Founded in 1998, TransMedics went public in 2019 and has established itself as a leader in transforming transplant outcomes for patients with end-stage organ failure.